Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

BACKGROUND: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy has been approved for TNBC and cytotoxic agents remain the mainstay of treatment. Ixazomib is a s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Burgstaller, Sonja, Fuchs, David, Rossmann, Dieter, Balic, Marija, Egle, Daniel, Rumpold, Holger, Singer, Christian F., Bartsch, Rupert, Petru, Edgar, Melchardt, Thomas, Ulmer, Hanno, Mlineritsch, Brigitte, Greil, Richard
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220453/
https://ncbi.nlm.nih.gov/pubmed/30400780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4979-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia